• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Topical ointment for psoriasis therapy gets FDA's NDA nod

Article

Washington -- The Food and Drug Administration has approved the new drug application (NDA) for Taclonex, a topical ointment for the treatment of psoriasis vulgaris in adults.

Washington -- The Food and Drug Administration has approved the new drug application (NDA) for Taclonex, a topical ointment for the treatment of psoriasis vulgaris in adults. Taclonex is sold outside the United States as Dovobet and Daivobet.

Officials of Warner Chilcott, Danish drug company LEO Pharma's exclusive licensee of Taclonex in the United States, say they expect to launch the drug in the first half of this year.

More than 4.5 million adults in the United States have been diagnosed with psoriasis, and about 150,000 new cases are diagnosed annually.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.